CXCL10 and cancer: A recent study showed that RORγt agonist (8‐074) promotes monocyte‐derived dendritic cells through CXCL10 in cancers to enhance anti‐PD‐1 therapy.[47] In order to determine whether the T. gondii‐induced CD64+MAR‐1+CD11b+ DCs could suppress tumor growth like the reported agonist, we administrated an in vivo adoptive transfer assay and confirmed the anti‐tumor ability of CD64+MAR‐1+CD11b+ DCs.